Potter WZ - Search Results

1

Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease.

Bodick NC, Offen WW, Levey AI, Cutler NR, Gauthier SG, Satlin A, Shannon HE, Tollefson GD, Rasmussen K, Bymaster FP, Hurley DJ, Potter WZ, Paul SM. Bodick NC, et al. Among authors: potter wz. Arch Neurol. 1997 Apr;54(4):465-73. doi: 10.1001/archneur.1997.00550160091022. Arch Neurol. 1997. PMID: 9109749 Clinical Trial.

2

Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia.

Shekhar A, Potter WZ, Lightfoot J, Lienemann J, Dubé S, Mallinckrodt C, Bymaster FP, McKinzie DL, Felder CC. Shekhar A, et al. Among authors: potter wz. Am J Psychiatry. 2008 Aug;165(8):1033-9. doi: 10.1176/appi.ajp.2008.06091591. Epub 2008 Jul 1. Am J Psychiatry. 2008. PMID: 18593778 Clinical Trial.

3

The double-blind variable placebo lead-in period: results from two antidepressant clinical trials.

Faries DE, Heiligenstein JH, Tollefson GD, Potter WZ. Faries DE, et al. Among authors: potter wz. J Clin Psychopharmacol. 2001 Dec;21(6):561-8. doi: 10.1097/00004714-200112000-00004. J Clin Psychopharmacol. 2001. PMID: 11763002 Review.

4

Evaluation of zimeldine in Alzheimer's disease. Cognitive and biochemical measures.

Cutler NR, Haxby J, Kay AD, Narang PK, Lesko LJ, Costa JL, Ninos M, Linnoila M, Potter WZ, Renfrew JW, et al. Cutler NR, et al. Among authors: potter wz. Arch Neurol. 1985 Aug;42(8):744-8. doi: 10.1001/archneur.1985.04210090008003. Arch Neurol. 1985. PMID: 2411246 Clinical Trial.

5

Dual monoamine modulation for improved treatment of major depressive disorder.

Tran PV, Bymaster FP, McNamara RK, Potter WZ. Tran PV, et al. Among authors: potter wz. J Clin Psychopharmacol. 2003 Feb;23(1):78-86. doi: 10.1097/00004714-200302000-00011. J Clin Psychopharmacol. 2003. PMID: 12544378 Review.

6

Duloxetine increases serotonin and norepinephrine availability in healthy subjects: a double-blind, controlled study.

Chalon SA, Granier LA, Vandenhende FR, Bieck PR, Bymaster FP, Joliat MJ, Hirth C, Potter WZ. Chalon SA, et al. Among authors: potter wz. Neuropsychopharmacology. 2003 Sep;28(9):1685-93. doi: 10.1038/sj.npp.1300209. Epub 2003 May 28. Neuropsychopharmacology. 2003. PMID: 12784100 Clinical Trial.

7

Assessing and interpreting treatment effects in longitudinal clinical trials with missing data.

Mallinckrodt CH, Sanger TM, Dubé S, DeBrota DJ, Molenberghs G, Carroll RJ, Potter WZ, Tollefson GD. Mallinckrodt CH, et al. Among authors: potter wz. Biol Psychiatry. 2003 Apr 15;53(8):754-60. doi: 10.1016/s0006-3223(02)01867-x. Biol Psychiatry. 2003. PMID: 12706959

8

Association of brain amyloid-β with cerebral perfusion and structure in Alzheimer's disease and mild cognitive impairment.

Mattsson N, Tosun D, Insel PS, Simonson A, Jack CR Jr, Beckett LA, Donohue M, Jagust W, Schuff N, Weiner MW; Alzheimer's Disease Neuroimaging Initiative. Mattsson N, et al. Brain. 2014 May;137(Pt 5):1550-61. doi: 10.1093/brain/awu043. Epub 2014 Mar 12. Brain. 2014. PMID: 24625697 Free PMC article.

9

Concentrations of desipramine in elderly women.

Cutler NR, Zavadil AP 3rd, Eisdorfer C, Ross RJ, Potter WZ. Cutler NR, et al. Among authors: potter wz. Am J Psychiatry. 1981 Sep;138(9):1235-7. doi: 10.1176/ajp.138.9.1235. Am J Psychiatry. 1981. PMID: 6791512

10

Temporal association between depression-dependent dyskinesias and high urinary phenylethylamine output.

Linnoila M, Karoum F, Cutler NR, Potter WZ. Linnoila M, et al. Among authors: potter wz. Biol Psychiatry. 1983 Apr;18(4):513-6. Biol Psychiatry. 1983. PMID: 6860726 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

342 results

Search Page

Filters